Evidence map›Paper›PMID 28502769›Full record

ArticleCell2017

Tracing the Enterococci from Paleozoic Origins to the Hospital.

François Lebreton, Abigail L Manson, Jose T Saavedra, Timothy J Straub, Ashlee M Earl, Michael S Gilmore

Abstract read
In one paragraph

Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

166 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. A genomic snapshot of hospital-adapted CC17 vancomycin-resistant Enterococcus faecium colonising high-risk patients in Serbia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  9. Review
  10. Article
  11. Draft genome sequences forMicrobiology resource announcements · 2026
    Article
  12. Antibiotics (Basel, Switzerland) · 2026
    Article
  13. Characterization ofPHAGE (New Rochelle, N.Y.) · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Contact dependent suppression ofbioRxiv : the preprint server for biology · 2026
    Article
  18. Article
  19. Microorganisms · 2026
    Review
  20. Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

François LebretonDepartment of Ophthalmology and Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02114, USA; Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA; Infectious Disease & Microbiome Program, Broad Institute, Cambridge, MA 02142, USA.
Abigail L MansonInfectious Disease & Microbiome Program, Broad Institute, Cambridge, MA 02142, USA.
Jose T SaavedraDepartment of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA.
Timothy J StraubInfectious Disease & Microbiome Program, Broad Institute, Cambridge, MA 02142, USA.
Ashlee M EarlInfectious Disease & Microbiome Program, Broad Institute, Cambridge, MA 02142, USA. Electronic address: aearl@broadinstitute.org.
Michael S GilmoreDepartment of Ophthalmology and Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02114, USA; Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA 02114, USA; Infectious Disease & Microbiome Program, Broad Institute, Cambridge, MA 02142, USA. Electronic address: michael_gilmore@meei.harvard.edu.

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI NEAFSEY, DANIEL E · 2014 to 2024
$66.5M
Technical Mother Machine CoreP01AI083214 · NIAID · SCHEPENS EYE RESEARCH INSTITUTE · PI Michael S Gilmore · 2009 to 2026
$39.4M
E. faecalis Pathogenicity IslandR01AI072360 · NIAID · SCHEPENS EYE RESEARCH INSTITUTE · PI GILMORE, MICHAEL S · 2007 to 2017
$3.8M
NIAID NIH HHS HHSN272200900018CNIAID NIH HHS P01 AI083214NIAID NIH HHS R01 AI072360NIAID NIH HHS U19 AI110818
6 · The paper itself

Abstract

We examined the evolutionary history of leading multidrug resistant hospital pathogens, the enterococci, to their origin hundreds of millions of years ago. Our goal was to understand why, among the vast diversity of gut flora, enterococci are so well adapted to the modern hospital environment. Molecular clock estimation, together with analysis of their environmental distribution, phenotypic diversity, and concordance with host fossil records, place the origins of the enterococci around the time of animal terrestrialization, 425-500 mya. Speciation appears to parallel the diversification of hosts, including the rapid emergence of new enterococcal species following the End Permian Extinction. Major drivers of speciation include changing carbohydrate availability in the host gut. Life on land would have selected for the precise traits that now allow pathogenic enterococci to survive desiccation, starvation, and disinfection in the modern hospital, foreordaining their emergence as leading hospital pathogens.

Indexed as

Biological EvolutionAnimalsCommunicable Diseases, EmergingCross InfectionDrug Resistance, BacterialEnterococcusGenetic SpeciationHost-Pathogen InteractionsLarvaMothsPhylogenyRNA, Ribosomal, 16SRNA, Ribosomal, 16Santibiotic resistancecommensalearly lifeEnterococcushospital acquired infectionoriginsPaleozoicspeciationterrestrialization

Identifiers

PMID28502769
PMCPMC5499534

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.